About this Research Topic
Bladder cancer is currently one of the most common cancer worldwide with over approximately 200,000 deaths reported on an annual basis. Bladder cancer is a heterogenous disease, divided into two types: non-muscle-invasive bladder cancer (NMIBC) accounting for 75% of bladder cancer cases and muscle invasive bladder cancer (MIBC) which accounts for the remaining 25% of cases. NMIBC has been demonstrated to be aggressive with a high recurrence rate whereas MIBC spreads into the detrusor muscle of the bladder, has been found to have a poor prognosis and can highly lead to metastatic tumor progression. Treatment and therapeutic approaches are essential to improve the poor prognosis, low survival rate and morbidity of the disease.
The standardized treatment for clinically localized MIBC patients involves neoadjuvant chemotherapy which is followed by radical cystectomy with the potential of pelvic lymphadenectomy. However, up to 50% of MIBC patients have a local relapse or distant metastasis primarily from circulated micrometastases which has led to a poor 5-year overall survival rate of approximately 50-60%. Alternative therapeutic strategies including transurethral resection of bladder tumor (TURBT), radiotherapy therapy and concurrent chemotherapy are potential options for MIBC patients. There are currently studies which explore the disease management of neoadjuvant cisplatin-based chemotherapy of MIBC as well as the role of neoadjuvant immunotherapy. This area of research is currently developing with the goal of improving treatment and understanding the impact on MIBC patients.
This Research Topic aims to generate a discussion on the neoadjuvant chemotherapy of muscle-invasive bladder cancer and how it can help improve the poor survival rate and prognosis for bladder cancer patients. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The standardized treatment for clinically localized MIBC patients involves neoadjuvant chemotherapy which is followed by radical cystectomy with the potential of pelvic lymphadenectomy. However, up to 50% of MIBC patients have a local relapse or distant metastasis primarily from circulated micrometastases which has led to a poor 5-year overall survival rate of approximately 50-60%. Alternative therapeutic strategies including transurethral resection of bladder tumor (TURBT), radiotherapy therapy and concurrent chemotherapy are potential options for MIBC patients. There are currently studies which explore the disease management of neoadjuvant cisplatin-based chemotherapy of MIBC as well as the role of neoadjuvant immunotherapy. This area of research is currently developing with the goal of improving treatment and understanding the impact on MIBC patients.
This Research Topic aims to generate a discussion on the neoadjuvant chemotherapy of muscle-invasive bladder cancer and how it can help improve the poor survival rate and prognosis for bladder cancer patients. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: bladder cancer, muscle-invasive bladder cancer, MIBC, chemotherapy, treatment
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
